Use of neuronal nitric oxide synthase inhibitors for immunotherapy in melanoma patients
View Patent ↗Disclosed herein are methods and compositions for administering immunotherapy to a subject in need thereof and for treating a subject in need thereof, where in the methods the subject is administered an effective amount of an inhibitor of nNOS for inducing an immunotherapeutic response in the subject and for treating the subject. The disclosed methods and composition may be utilized for treating a subject having a cell proliferative disease or disorder such as melanoma.
1. A method for treating melanoma characterized by elevated expression levels of programmed death-ligand 1 (PD-L1) in a subject in need thereof, the method comprising administering to the subject an effective amount of an inhibitor of neuronal nitric oxide synthase (nNOS) for decreasing expression of PD-L1 and treating the melanoma, wherein the inhibitor of nNOS is the compound MAC-3-190 having a formula:
or a suitable pharmaceutical salt, solvate, or hydrate thereof.
2. The method of claim 1 , further comprising administering to the subject IFN-α.
3. The method of claim 1 , further comprising administering to the subject a PD-L1 inhibitor or a programmed death-receptor 1 (PD-1) inhibitor.
4. The method of claim 1 , further comprising administering dacarbazine to the subject.
5. The method of claim 1 , further comprising administering temozolomide to the subject.
6. A method for treating melanoma characterized by elevated expression levels of programmed death-ligand 1 (PD-L1) in a subject in need thereof, the method comprising administering to the subject an effective amount of an inhibitor of neuronal nitric oxide synthase (nNOS) for decreasing expression of PD-L1 and treating the melanoma, wherein the inhibitor of nNOS is the compound HH044 having a formula:
or a suitable pharmaceutical salt, solvate, or hydrate thereof.
7. The method of claim 6 , further comprising administering to the subject IFN-α.
8. The method of claim 6 , further comprising administering to the subject a PD-L1 inhibitor or a programmed death-receptor 1 (PD-1) inhibitor.
9. The method of claim 6 , further comprising administering dacarbazine to the subject.
10. The method of claim 6 , further comprising administering temozolomide to the subject.